Two other miRNAs, miRNA-185 and miRNA-342, can block SREBP-1/2 and its downregulated targets, FASN and hydroxy-3-methylglutaryl CoA reductase (HMGCR), to inhibit prostate cancer tumorigenicity (78). Here, FASN is linked to prostate carcinoma.